SCHEMBL9233227

SCHEMBL9233227

O=C1NC(=O)C2(CCN(Cc3ccccc3)C2)N1

nearest known ligand 0.54

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CRBN Q96SW2 3/20 0.54
DDB1 Q16531 2/20 0.54
LTA4H P09960 2/20 0.53
OPRM1 P35372 1/20 0.47
OPRD1 P41143 1/20 0.47
OPRK1 P41145 1/20 0.47
OPRL1 P41146 1/20 0.47
TSHR P16473 2/20 0.46
CYP3A4 P08684 2/20 0.46
CYP2D6 P10635 2/20 0.46
KMT2A Q03164 2/20 0.46
MEN1 O00255 1/20 0.46
ALDH1A1 P00352 1/20 0.46
CYP2C9 P11712 1/20 0.46
CYP2C19 P33261 1/20 0.46
HIF1A Q16665 1/20 0.46
HSD17B10 Q99714 1/20 0.45
DRD2 P14416 1/20 0.44
SIGMAR1 Q99720 1/20 0.44
GAA P10253 1/20 0.44

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL30069377 1.00 CRBN (0.54) CRBNDDB1LTA4HOPRM1OPRD1
SCHEMBL13744397 0.92 CYP2D6 (0.52) CRBNDDB1LTA4HTSHRCYP3A4
SCHEMBL5192402 0.91 LTA4H (0.61) CRBNDDB1LTA4HOPRM1OPRD1
SCHEMBL22144489 0.88 GAA (0.53) CRBNDDB1LTA4HOPRM1OPRD1
SCHEMBL18491021 0.84 PDE7A (0.52) LTA4HTSHRCYP3A4CYP2D6KMT2A
SCHEMBL20608023 0.79 OTUD7B (0.52) OPRM1OPRD1OPRK1OPRL1TSHR
SCHEMBL20608029 0.79 OTUD7B (0.62) OPRM1OPRD1OPRK1OPRL1TSHR
SCHEMBL20721888 0.79 OTUD7B (0.60) LTA4HOPRM1OPRD1OPRK1OPRL1
SCHEMBL11838498 0.78 LTA4H (0.57) CRBNLTA4HALDH1A1SIGMAR1SSTR5
SCHEMBL13052383 0.78 PDE7A (0.58) LTA4HOPRM1OPRD1OPRK1OPRL1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20240018156-A1 SPIROCYCLIC COMPOUNDS C4 THERAPEUTICS, INC. (US) 2024-01-18 US disclosed
US-11623929-B2 Spirocyclic compounds C4 THERAPEUTICS, INC. (US) 2023-04-11 US disclosed
US-20210070763-A1 SPIROCYCLIC COMPOUNDS C4 THERAPEUTICS, INC. (US) 2021-03-11 US disclosed
EP-0677522-A1 8-METHOXYQUINOLONECARBOXYLIC ACID DERIVATIVE YOSHITOMI PHARMACEUTICAL INDUSTRIES, LTD. (JP) 1995-10-18 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20210070763-A1 SPIROCYCLIC COMPOUNDS CRBN, XIAP, RBX1 CRBN 1/4885DDB1 153/4885LTA4H 4524/4885
US-20240018156-A1 SPIROCYCLIC COMPOUNDS CRBN, XIAP, RBX1 CRBN 1/4885DDB1 153/4885LTA4H 4524/4885
US-11623929-B2 Spirocyclic compounds CRBN, XIAP, RBX1 CRBN 1/4885DDB1 153/4885LTA4H 4524/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.